🔗 Share this article

Given that America continues making unprecedented revisions to its vaccination recommendations, a particular individual appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by questioning coronavirus vaccinations in the pandemic and has concentrated on possible fatalities following COVID-19 immunization in her brief position at the Food and Drug Administration.

Proposed Changes to Childhood Vaccine Schedule

Public health authorities were set to reveal major changes to the pediatric immunization program recently, bringing the US with the Danish national calendar, it is understood – a significant shift that would put the US out of alignment with a large portion of the international standard with no evidence for public health gain. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Høeg is set to speak at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to head the center this year.

A Shift at the Agency

Høeg's temporary position could signify a closer partnership between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a greater focus upon dismantling already-approved vaccines at the FDA.

The new acting director has frequently advocated for halting certain pediatric shot schedules in the US so as to align more like the Danish model, a nation with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccines – usually the purview of Prasad, head of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Expertise

Høeg has no obvious background in drug development, oversight or management, which has been customary for previous leaders of the CBER. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in managing a large organization. She is not an expert in drug approvals.”

Former directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that former directors who led CBER have had.”

This division has an immense workload at the agency, she stated.

“The public just focuses on the new drug program, but the generic program authorizes numerous generic drugs. There is also a biologic copycat branch, over-the-counter program and more, and all of those have to be supervised,” Woodcock said. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial management aspect to the job, which manages more than 5,000 staff members. “It is a huge administrative position, if you execute it properly,” she concluded.

Official Statement and Controversial Programs

Regarding inquiries about Høeg’s credentials and whether this assignment signifies increased cooperation among agency officials on vaccines, a spokesperson responded that the “inquiries rely on inaccurate premises”.

“Her experience aligns with the responsibilities of her job,” the spokesperson explained, pointing to the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg inherits the commissioner’s recently launched priority voucher program, a contentious rapid therapy clearance system that apparently concerned her predecessors. “How are these therapies being picked for this fast-track system? Who makes the decisions?” Dr. Howard said. “There is a lot of secrecy happening at the regulatory body right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed rules of most medications, except for vaccines.”

Established Past Work on Immunizations

Concerning immunizations, Høeg has a more documented, if problematic, past, some experts said. She published a research paper using non-validated public submissions to estimate the incidence of myocarditis after COVID-19 vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the new administration included changing regulations for recently developed shots and discontinuing “non-essential” vaccines, she said following the vote on a online show. At the agency, Dr. Høeg has reportedly suggested barring young men from receiving COVID-19 vaccinations.

“She’s an thorough true believer who begins with her beliefs and tailors the evidence to fit the evidence in a very misleading, dishonest fashion,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|